Loading…
Allogene Therapeutics, Inc. is projected to rise to $3.32 by 2027, a +47% move from its current price of $2.25. ALLO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.16 | $2.25 | $2.35 | +0.08% |
| May 30 | $2.13 | $2.25 | $2.39 | +0.15% |
| May 31 | $2.10 | $2.26 | $2.42 | +0.23% |
| Jun 1 | $2.08 | $2.26 | $2.45 | +0.31% |
| Jun 2 | $2.06 | $2.26 | $2.47 | +0.39% |
| Jun 3 | $2.05 | $2.26 | $2.50 | +0.47% |
| Jun 4 | $2.03 | $2.26 | $2.52 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.03 | $2.26 | $2.52 | +0.54% |
| Week 2 | $1.95 | $2.27 | $2.65 | +1.09% |
| Week 3 | $1.90 | $2.29 | $2.75 | +1.64% |
| Week 4 | $1.85 | $2.30 | $2.85 | +2.19% |
| Week 5 | $1.82 | $2.31 | $2.94 | +2.74% |
| Week 6 | $1.79 | $2.32 | $3.02 | +3.30% |
| Week 7 | $1.76 | $2.34 | $3.11 | +3.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It works on a pipeline of multiple allogeneic CAR T cell product candidates, utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
The company is developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL); it is also advancing ALLO-316, an engineered allogeneic CAR T cell product candidate targeting CD70 for renal cell carcinoma (RCC); and ALLO-329, targeting both CD19 and CD70 for autoimmune diseases such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. (ALLO) is currently priced at $2.25 with a market cap of $776.6M, and it holds the 2681st rank by market capitalization. The stock’s current level sits near a short-term range that reflects a blend of technical signals and projected volatility.
The overall price outlook from the provided forecast shows a transition from neutral in 2026 to bullish momentum in the coming years, with meaningful upside projected through 2030 and beyond.
The forecast for 2026 places the average at $2.25 with a neutral sentiment, suggesting limited upside in that year. From 2027 onward, the outlook turns bullish, with the average price rising to $3.32 in 2027, then higher in subsequent years (e.g., $4.46 by 2030, $16.32 by 2040, and $28.63 by 2050), accompanied by strong ROI figures. This indicates a potential long-term upside trajectory despite near-term volatility.
A major floor 35.6% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 7.6% above — a clean break opens room to run.
A major ceiling 36.0% above — clearing it would confirm fresh momentum.
Key ALLO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALLO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.05 | Buy | $2.10 | Buy |
| MA 10 | $2.05 | Buy | $2.09 | Buy |
| MA 20 | $2.14 | Buy | $2.14 | Buy |
| MA 50 | $2.30 | Sell | $2.20 | Buy |
| MA 100 | $2.12 | Buy | $2.09 | Buy |
| MA 200 | $1.69 | Buy | $1.91 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.42 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 61.11 | Neutral |
| Williams %R (14) | -18.18 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -1.32 | Sell |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 81.82 | Sell |
| TRIX (15) | -0.54 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 63.76 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 2.12 | Buy |
| ADX (14) | 12.65 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bullish in sentiment. The RSI14 is 50, and the stock trades above the 200-day simple moving average (SMA200) of $1.69 while trading near the 50-day simple moving average (SMA50) of $2.30. Support is at $1.89 and resistance at $2.42, framing a near-term path with upside potential.
Over the last 30 days, the price has traded within a range of $1.72 to $2.94, highlighting notable volatility within a relatively tight band around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $2.25 | $3.64 | 0% | Neutral | |
| $2.51 | $3.32 | $4.72 | +47% | Bullish | |
| $2.80 | $3.87 | $5.78 | +72% | Bullish | |
| $2.62 | $3.75 | $5.83 | +67% | Bullish | |
| $3.01 | $4.46 | $7.15 | +98% | Bullish | |
| $3.58 | $5.45 | $9.00 | +142% | Bullish | |
| $3.96 | $6.22 | $10.52 | +176% | Bullish | |
| $5.15 | $8.30 | $14.37 | +269% | Bullish | |
| $5.59 | $9.24 | $16.34 | +311% | Bullish | |
| $5.29 | $8.98 | $16.18 | +299% | Bullish | |
| $8.55 | $16.32 | $31.84 | +625% | Bullish | |
| $12.89 | $28.63 | $62.62 | +11.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.35 | $2.25 | $2.66 | +0.00% |
| June 2026 | $1.96 | $2.33 | $2.85 | +3.50% |
| July 2026 | $2.01 | $2.41 | $3.01 | +3.68% |
| August 2026 | $1.95 | $2.37 | $3.00 | -1.69% |
| September 2026 | $1.97 | $2.42 | $3.10 | +1.79% |
| October 2026 | $2.12 | $2.62 | $3.39 | +8.40% |
| November 2026 | $2.20 | $2.73 | $3.58 | +4.41% |
| December 2026 | $2.21 | $2.76 | $3.64 | +0.97% |
Click any year to see its month-by-month ALLO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALLO to range from $1.35 to $3.64 through 2026. The $2.25 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALLO price prediction for 2027 points to an average of $3.32 (low $2.51, high $4.72) — a potential gain of +47% on today's $2.25. Momentum favours further upside here.
In 2028, ALLO is projected to trade between $2.80 and $5.78, averaging $3.87 — a potential gain of +72% from today's $2.25. That is up +17% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Allogene Therapeutics, Inc.'s 2029 outlook centres on $3.75, within a $2.62 to $5.83 range. That is -3% versus the projected 2028 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2030, ALLO could reach as high as $7.15, with a base case around $4.46 and support toward $3.01 — roughly +98% from $2.25. Buyers look set to stay in control over this stretch.
Expect ALLO to range from $3.58 to $9.00 through 2031. The $5.45 average target implies a +142% move from current prices. That is up +22% on the projected 2030 average. Momentum favours further upside here.
The ALLO price prediction for 2032 points to an average of $6.22 (low $3.96, high $10.52) — a potential gain of +176% on today's $2.25. Buyers look set to stay in control over this stretch.
In 2033, ALLO is projected to trade between $5.15 and $14.37, averaging $8.30 — a potential gain of +269% from today's $2.25. That is up +34% on the projected 2032 average. Momentum favours further upside here.
Allogene Therapeutics, Inc.'s 2034 outlook centres on $9.24, within a $5.59 to $16.34 range. That is up +11% on the projected 2033 average. That marks a +311% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALLO could reach as high as $16.18, with a base case around $8.98 and support toward $5.29 — roughly +299% from $2.25. Momentum favours further upside here.
Expect ALLO to range from $8.55 to $31.84 through 2040. The $16.32 average target implies a +625% move from current prices. That is up +82% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALLO price prediction for 2050 points to an average of $28.63 (low $12.89, high $62.62) — a potential gain of +11.7x on today's $2.25. Momentum favours further upside here.
Investing $1,000 in ALLO today (≈ 444.444444 ALLO) could be worth
$12,726.26
+$11,726.26 (+1173%) by 2050 · US Dollar
Based on the average projected ALLO price of $28.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALLOwould be worth at today's price.
$1,000 invested in ALLO on May 27, 2025 (≈ 925.925889 ALLO) would be worth
$2,083.33
+$1,083.33 (+108.3%) today · 2.08× · US Dollar
Based on a ALLO entry price of $1.08 vs. today's $2.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.9 | $1,184.21 | +18.4% |
| 1 month ago | $2.25 | $1,000 | +0.0% |
| 3 months ago | $2.73 | $824.18 | -17.6% |
| 6 months ago | $1.46 | $1,541.1 | +54.1% |
| 1 year ago | $1.08 | $2,083.33 | +108.3% |
| All time (5.0y) ago | $25.37 | $88.69 | -91.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALLO forecast.
Our base-case forecast reaches $4.50 around 2031.
Implied market cap at $4.50: $1.55B
Looking out to 2030, the average forecast is $4.46 with a minimum of $3.01 and a maximum of $7.15, yielding an estimated ROI of 98.3% and a bullish sentiment. By 2040, the average forecast climbs to $16.32 with a wide range of $8.55 to $31.84, signaling a substantial upside with a 625.3% ROI and bullish sentiment. The 2050 forecast shows an average of $28.63, a range from $12.89 to $62.62, and a projected ROI of 1172.6%, with continued bullish sentiment.
In the near term, 2027 and 2028 forecasts show continued upside, with 2027 at an average of $3.32 and 2028 at $3.87, both bullish. The sequence culminates in a long-run trajectory where the asset experiences multiple years of growth, underpinned by bullish sentiment, though these figures are estimates and not guarantees.
Overall, the multi-year view suggests meaningful upside potential from 2027 onward, punctuated by pronounced gains by 2040 and 2050, while acknowledging the inherent uncertainty of price forecasts.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.46, with a range from $3.01 to $7.15, and an estimated ROI of 98.3%, with a bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward and potential upside, with the 2050 average price at $28.63 and ROI of 1172.6%, though 2026 is neutral and these are estimates, not guarantees.
Yes, the forecast shows 2033 with an average of $8.30, 2034 with $9.24, and 2040 with $16.32, indicating that a $10 level is expected to be reached on or before 2040 based on the averages.
Current price is $2.25 and market cap is $776.6M.
The 30-day range is $1.72 to $2.94.
Allogene Therapeutics, Inc. Community Discussion
0Share your Allogene Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.